Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease

Lind, Tore; Rydberg, Lars; Kylebäck, Anders; Jönsson, Andreas; Andersson, Tommy; Hasselgren, Gunnar; Holmberg, Johan; Röhss, Kerstin

doi:10.1046/j.1365-2036.2000.00813.x

Cited by 272 publications

(238 citation statements)

References 16 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…The AUC of esomeprazole in people has been reported to be higher than that of omeprazole of the same dose 3. The efficacy of esomeprazole in suppressing gastric acid is closely related to the subject's total exposure to the drug (ie, the AUC), and for that reason, esomeprazole has been shown to result in better acid suppression than omeprazole of equal doses in human studies 3, 5, 6, 25, 26. This difference in efficacy between the current study and a previous study may be due to the higher AUC for esomeprazole than for omeprazole, and the difference in study design and formulations (enteric‐coated granules versus a delayed‐release tablet), or it may due to the small study population and inclusion of only 1 breed in this study.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs

Hwang

Jeong

Song

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundEsomeprazole is an S‐enantiomer of omeprazole that has favorable pharmacokinetics and efficacious acid suppressant properties in humans. However, the pharmacokinetics and effects on intragastric pH of esomeprazole in dogs have not been reported.ObjectiveTo determine the pharmacokinetics of esomeprazole administered via various routes (PK study) and to investigate the effect of esomeprazole on intragastric pH with a Bravo pH monitoring system (PD study).AnimalsSeven adult male Beagle dogs and 5 adult male Beagle dogs were used for PK and PD study, respectively.MethodsBoth studies used an open, randomized, and crossover design. In the PK study, 7 dogs received intravenous (IV), subcutaneous (SC), and oral doses (PO) of esomeprazole (1 mg/kg). Each treatment period was separated by a washout period of at least 10 days. Esomeprazole plasma concentrations were measured by HPLC/MS/MS. In the efficacy study, intragastric pH was recorded without medication (baseline pH) and following IV, SC, and PO esomeprazole dosing regimens (1 mg/kg) in 5 dogs.ResultsThe bioavailability of esomeprazole administered as PO enteric‐coated granules and as SC injections was 71.4 and 106%, respectively. The half‐life was approximately 1 hour. Mean ± SD percent time intragastric pH was ≥3 and ≥4 was 58.9 ± 21.1% and 40.9 ± 17.3% for IV group, 75.8 ± 16.4% and 62.7 ± 17.7% for SC group, 88.2 ± 8.9% and 82.5 ± 7.7% for PO group, and 12.5 ± 3.6% and 3.7 ± 1.8% for baseline. The mean percent time with intragastric pH was ≥3 or ≥4 was significantly increased regardless of the dosing route (P < .05).ConclusionThe PK parameters for PO and SC esomeprazole administration were favorable, and esomeprazole significantly increased intragastric pH after IV, PO, and SC administration. IV and SC administration of esomeprazole might be useful when PO administration is not possible. No significant adverse effects were observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs

Hwang

Jeong

Song

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…19 More recently, it has been reported that oral and intravenous pantoprazole are also equivalent, even when administered at a high dose (280-290 mg daily) in healthy volunteers, comparable to doses used for the management of upper gastrointestinal tract haemorrhage (80 mg bolus, followed by an infusion of 8 mg/ h). 19,20 This study was conducted in healthy subjects, and the results should therefore be extrapolated with caution to patients in an intensive care unit (ICU) and those who are being treated for upper gastrointestinal bleeding. The baseline pH data indicate that all subjects had normal gastric secretory function, unlike some ICU patients in whom gastric acid secretion may be compromised by severe concomitant illness.…”

Section: Discussionmentioning

confidence: 99%

Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects

Armstrong

Bair

James

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Intravenous (IV) proton-pump inhibitor therapy is used in patients who cannot take oral medications or require greater acid suppression. Oral esomeprazole produces greater acid suppression than oral pantoprazole; however, no comparative data exist for oral esomeprazole and IV pantoprazole. Aim: To compare acid suppression (time with pH > 3.0, 4.0, 5.0 and 6.0) produced by standard doses of oral esomeprazole and IV pantoprazole in healthy subjects. Methods: A randomized, two-way crossover study in 30 subjects receiving oral esomeprazole (40 mg o.d.) or IV pantoprazole (40 mg o.d.) for 5 days followed by a 2-week washout period before the second 5-day drug

show abstract

“…On further detailed evaluation during the abstraction process, one of these studies was found to have been carried out without blinding and was excluded, 12 two were found to have a Jadad score of only two and were excluded from further analysis 13,29 and one study's primary outcome was based on surrogate end-points (intra-oesophageal pH) and was also excluded. 18 The findings from the systematic review of the remaining 32 studies are summarized and presented in Tables 4-8. The focused clinical questions that had been formulated prior to the search were then addressed using these data.…”

Section: Resultsmentioning

confidence: 99%

The Frontiers of Reflux Disease

Vakil

2006

Dig Dis Sci

View full text Add to dashboard Cite

Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease

Abstract: Esomeprazole provides more effective acid control than omeprazole, with reduced interpatient variability, thereby offering the potential for improved efficacy in acid-related diseases.

Cited by 272 publications

References 16 publications

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs

Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects

The Frontiers of Reflux Disease

Contact Info

Product

Resources

About